Trials / Terminated
TerminatedNCT00507338
Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI
A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Archemix Corp. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
ARC1779 is a novel drug being tested in patients undergoing angioplasty and stenting as their primary treatment for heart attack.
Detailed description
Adjunctive anti-thrombotic therapy for PCI of AMI may be improved by incorporation of a novel anti-platelet therapeutic principle, von Willebrand Factor antagonism. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. This study is intended to provide dose-ranging and clinical proof of concept for ARC1779 in a primary PCI population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | PCI | early PCI for NSTEMI; primary PCI for STEMI |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-07-26
- Last updated
- 2009-01-09
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT00507338. Inclusion in this directory is not an endorsement.